Erasca reported preliminary tumor-shrinking data for its RAS-targeting pill ERAS-0015 in advanced pancreatic and non-small cell lung cancer, describing results that exceeded its expectations. The company said data were collected from studies in the U.S. and China. Erasca claimed ERAS-0015 shrank tumors in 40% of patients with advanced pancreatic cancer and 62% of patients with advanced NSCLC. The company emphasized that the datasets are still preliminary, but highlighted tolerability and “clinical benefit” as key differentiators. The update arrives after Revolution Medicines’ daraxonrasib drew attention with overall survival gains in advanced pancreatic cancer, setting up head-to-head attention on mechanism-led RAS programs.